SG11201911520UA - Agent for preventing or treating tauopathy - Google Patents
Agent for preventing or treating tauopathyInfo
- Publication number
- SG11201911520UA SG11201911520UA SG11201911520UA SG11201911520UA SG11201911520UA SG 11201911520U A SG11201911520U A SG 11201911520UA SG 11201911520U A SG11201911520U A SG 11201911520UA SG 11201911520U A SG11201911520U A SG 11201911520UA SG 11201911520U A SG11201911520U A SG 11201911520UA
- Authority
- SG
- Singapore
- Prior art keywords
- preventing
- agent
- treating tauopathy
- tauopathy
- treating
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
Landscapes
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2017109886 | 2017-06-02 | ||
| JP2017128473 | 2017-06-30 | ||
| PCT/JP2018/021225 WO2018221731A1 (en) | 2017-06-02 | 2018-06-01 | Agent for preventing or treating tauopathy |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201911520UA true SG11201911520UA (en) | 2020-01-30 |
Family
ID=64454837
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201911520UA SG11201911520UA (en) | 2017-06-02 | 2018-06-01 | Agent for preventing or treating tauopathy |
Country Status (15)
| Country | Link |
|---|---|
| US (2) | US20200155505A1 (en) |
| EP (1) | EP3636261A4 (en) |
| JP (3) | JP7370859B2 (en) |
| KR (3) | KR20220101001A (en) |
| CN (1) | CN110691594A (en) |
| AU (1) | AU2018277982B2 (en) |
| BR (1) | BR112019024878A2 (en) |
| CA (1) | CA3067456C (en) |
| IL (1) | IL270912A (en) |
| MX (1) | MX2019014300A (en) |
| NZ (1) | NZ759657A (en) |
| RU (1) | RU2739199C1 (en) |
| SG (1) | SG11201911520UA (en) |
| WO (1) | WO2018221731A1 (en) |
| ZA (1) | ZA201907975B (en) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG11201911519UA (en) | 2017-06-02 | 2020-01-30 | Fujifilm Toyama Chemical Co Ltd | AGENT FOR REDUCING AMOUNT OF AMYLOID ß PROTEIN |
| CN116473962A (en) | 2017-06-02 | 2023-07-25 | 富士胶片富山化学株式会社 | Agent for preventing or treating brain atrophy |
| JP7133547B2 (en) | 2017-06-02 | 2022-09-08 | 富士フイルム富山化学株式会社 | Preventive or therapeutic agent for spinocerebellar degeneration |
| EP3636262A4 (en) | 2017-06-02 | 2020-06-10 | FUJIFILM Toyama Chemical Co., Ltd. | Agent for preventing or treating alzheimer-type dementia |
| US11548878B2 (en) * | 2017-10-30 | 2023-01-10 | Fujifilm Toyama Chemical Co., Ltd. | Emopamil binding protein binding agent and use thereof |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RO122203B1 (en) | 2001-10-19 | 2009-02-27 | Toyama Chemical Co., Ltd. | Alkyl ether derivatives and salts thereof |
| EP2389937B1 (en) | 2002-06-14 | 2018-08-15 | Toyama Chemical Co., Ltd. | Medicinal composition for improving brain function |
| PT2265578E (en) * | 2008-03-04 | 2015-10-21 | Vernalis R&D Ltd | Azetidine derivatives |
| TR201907882T4 (en) * | 2012-02-22 | 2019-06-21 | Fujifilm Toyama Chemical Co Ltd | Solid pharmaceutical composition containing 1- (3- (2- (1-Benzothiophen-5-yl) ethoxy) propyl) azetidin-3-ol or its salt |
| PL3100725T3 (en) * | 2014-01-31 | 2020-11-16 | Fujifilm Toyama Chemical Co., Ltd. | Post nerve injury rehabilitation effect-enhancing agent comprising an alkyl ether derivative or a salt thereof |
| WO2015188368A1 (en) * | 2014-06-13 | 2015-12-17 | Merck Sharp & Dohme Corp. | Pyrrolo[2,3-c]pyridines as imaging agents for neurofibrilary tangles |
| WO2016051799A1 (en) * | 2014-10-01 | 2016-04-07 | 学校法人同志社 | 2-aminohydroquinone derivative and tau aggregation inhibitor |
| AU2016214537B2 (en) * | 2015-02-02 | 2018-05-10 | Ucb Biopharma Sprl | 9H-pyrrolo-dipyridine derivatives |
| US20160324851A1 (en) * | 2015-05-07 | 2016-11-10 | Axovant Sciences, Ltd. | Methods of treating a neurodegenerative disease |
| EP3308782B1 (en) * | 2015-06-11 | 2022-01-19 | Toyama Chemical Co., Ltd. | Sigma-receptor binding agent |
| US11304928B2 (en) * | 2015-12-25 | 2022-04-19 | Fujifilm Toyama Chemical Co., Ltd. | Tablet comprising 1-(3-(2-(1-benzothiophen-5-yl)ethoxy)propyl)azetidin-3-ol or salt thereof |
-
2018
- 2018-06-01 JP JP2019521350A patent/JP7370859B2/en active Active
- 2018-06-01 MX MX2019014300A patent/MX2019014300A/en unknown
- 2018-06-01 CN CN201880035503.9A patent/CN110691594A/en active Pending
- 2018-06-01 KR KR1020227022765A patent/KR20220101001A/en not_active Application Discontinuation
- 2018-06-01 KR KR1020197035349A patent/KR20190141762A/en not_active IP Right Cessation
- 2018-06-01 SG SG11201911520UA patent/SG11201911520UA/en unknown
- 2018-06-01 NZ NZ759657A patent/NZ759657A/en unknown
- 2018-06-01 KR KR1020227022766A patent/KR20220101205A/en not_active Application Discontinuation
- 2018-06-01 US US16/617,552 patent/US20200155505A1/en not_active Abandoned
- 2018-06-01 AU AU2018277982A patent/AU2018277982B2/en active Active
- 2018-06-01 CA CA3067456A patent/CA3067456C/en active Active
- 2018-06-01 EP EP18809579.8A patent/EP3636261A4/en active Pending
- 2018-06-01 WO PCT/JP2018/021225 patent/WO2018221731A1/en active Application Filing
- 2018-06-01 RU RU2019138699A patent/RU2739199C1/en active
- 2018-06-01 BR BR112019024878-1A patent/BR112019024878A2/en active Search and Examination
-
2019
- 2019-11-25 IL IL270912A patent/IL270912A/en unknown
- 2019-11-29 ZA ZA2019/07975A patent/ZA201907975B/en unknown
-
2022
- 2022-02-28 JP JP2022028811A patent/JP2022060579A/en active Pending
- 2022-02-28 JP JP2022028810A patent/JP2022060578A/en active Pending
-
2023
- 2023-07-10 US US18/220,218 patent/US20230346745A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| MX2019014300A (en) | 2020-08-03 |
| RU2739199C1 (en) | 2020-12-21 |
| JP2022060579A (en) | 2022-04-14 |
| US20230346745A1 (en) | 2023-11-02 |
| JP7370859B2 (en) | 2023-10-30 |
| KR20220101205A (en) | 2022-07-19 |
| BR112019024878A2 (en) | 2020-06-16 |
| US20200155505A1 (en) | 2020-05-21 |
| WO2018221731A1 (en) | 2018-12-06 |
| EP3636261A1 (en) | 2020-04-15 |
| EP3636261A4 (en) | 2020-06-10 |
| KR20220101001A (en) | 2022-07-18 |
| JP2022060578A (en) | 2022-04-14 |
| CN110691594A (en) | 2020-01-14 |
| IL270912A (en) | 2020-01-30 |
| AU2018277982A1 (en) | 2019-12-19 |
| ZA201907975B (en) | 2021-09-29 |
| AU2018277982B2 (en) | 2021-04-08 |
| KR20190141762A (en) | 2019-12-24 |
| NZ759657A (en) | 2022-07-29 |
| CA3067456C (en) | 2023-03-14 |
| JPWO2018221731A1 (en) | 2020-04-09 |
| CA3067456A1 (en) | 2018-12-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA201905902B (en) | 2-heteroaryl-3-oxo-2,3-dihydropyridazine-4-carboxamides for the treatment of cancer | |
| EP3501527C0 (en) | Composition for preventing or treating mental disorder, containinglactobacillus | |
| ZA201907975B (en) | Agent for preventing or treating tauopathy | |
| SG11201705767PA (en) | Agent for preventing and/or treating amyotrophic lateral sclerosis | |
| GB201709402D0 (en) | Compounds for treating t-pll | |
| IL271018A (en) | Compounds for treating tnbc | |
| PL3243997T3 (en) | Escape door | |
| PT3348557T (en) | Compound for treating or preventing hyperuricemia or gout | |
| ZA201907973B (en) | Agent for preventing or treating brain atrophy | |
| PL3481933T3 (en) | Anti-greying agent | |
| SG11201700530PA (en) | Agent for improving brain function and agent for preventing or treating cognitive impairment | |
| ZA201907974B (en) | Agent for preventing or treating spinocerebellar ataxia | |
| EP3507838C0 (en) | Device for treating parts | |
| IL265249A (en) | Heterocyclic compound, and harmful-arthropod-controlling agent containing same | |
| SG11202001484QA (en) | Cytocidal agent | |
| HK1249044A1 (en) | Hypoestoxide, derivatives, related compounds, and agonists thereof for treatment or prevention of neurodegenerative diseases | |
| ZA201802268B (en) | Methods and compositions for preventing or treating cancer | |
| GB201714777D0 (en) | Agent | |
| GB201620641D0 (en) | Agent | |
| HUE051563T2 (en) | Pharmaceutical composition for preventing or treating cancer | |
| PL3413712T3 (en) | Disinfection agent | |
| ZA202103582B (en) | Dna-cutting agent | |
| ZA202103578B (en) | Dna-cutting agent | |
| GB201711677D0 (en) | Combination treatment | |
| GB201721379D0 (en) | Inhibitory agent |